Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shot shows promise for weight loss in chinese adults

NCT ID NCT05996848

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new weekly injection called CagriSema, which combines two drugs (cagrilintide and semaglutide), to help Chinese adults with obesity or overweight lose weight. About 300 participants received either CagriSema, semaglutide alone, or a placebo for around one year. The main goals were to see how much weight they lost and how many achieved at least a 5% reduction in body weight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If successful, this could provide a new weekly injection option for significant weight loss in Chinese adults with obesity or overweight.
What could go wrong
This is a Phase 3 trial, but results may not apply to all populations. Side effects from the drugs (like nausea or gastrointestinal issues) are possible, and the long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

300 people

The number who actually took part.

Started

Aug 2023

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * Age above or equal to 18 years at the time of signing informed consent 1. Body Mass Index (BMI) greater than or equal to 30.0 kilograms per square meter (kg/m\^2) or 2. BMI greater than or equal to 27.0 kg/m\^2 with the presence of at least one weight-related comorbidity including, but not limited to, type 2 diabetes mellitus, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease For participants with Type 2 diabetes (T2D) at screening the following criteria also apply: * Diagnosed with type 2 diabetes mellitus greater than equal to 180 days before screening * Treatment with either lifestyle intervention, or treatment with 1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose cotransporter 2 inhibitor (SGLT2i)), thiazolidinediones, or sulphonylureas (SUs) as a single agent or in combination) according to local label * Treatment with oral antidiabetic drugs should be stable (same drug(s), dose and dosing frequency) for at least 60 days before screening * Glycated Haemoglobin (HbA1c) 7 percent-10 percent (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as measured by the central laboratory at screening Exclusion Criteria: For participants without T2D at screening: * HbA1c greater than or equal to 6.5 percent (48 mmol/mol) as measured by the central laboratory at screening * History of type 1 or type 2 diabetes mellitus For participants with T2D at screening: * Clinically significant or severe hypoglycaemia within 6 months before screening or history of hypoglycaemia unawareness * Renal impairment with estimated glomerular filtration rate (eGFR) lesser than 30 milli liter per min/1.73 meter square (mL/min/1.73 m\^2), as measured by the central laboratory at screening * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity or overweight

Contacts and locations

Locations

  • Central Hospital of Minhang District, Shanghai-Endocrinology

    Shanghai, Shanghai Municipality, 201199, China

  • Central Hospital of Minhang District-Endocrinology

    Shanghai, Shanghai Municipality, 201199, China

  • Changzhou No.2 People's Hospital

    Changzhou, Jiangsu, 213003, China

  • Chinese People's Liberation Army General Hospital-Endocrinology

    Beijing, Beijing Municipality, 100853, China

  • Chongqing University Three Gorges Hospital

    Chongqing, Chongqing Municipality, 404000, China

  • Fujian Medical University Union Hospital-Endocrinology

    Fuzhou, Fujian, 350001, China

  • General Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, 300052, China

  • General Hospital of Tianjin Medical University-Endocrinology

    Tianjin, Tianjin Municipality, 300052, China

  • Hengshui People's Hospital (Harrison International Peace Hospital)-Endocrinology

    Hengshui, Hebei, 053000, China

  • Huaihe Hospital of Henan University

    Kaifeng, Henan, 475000, China

  • Huaihe Hospital of Henan University-Endocrinology

    Kaifeng, Henan, 475000, China

  • Huashan Hospital Fudan University

    Shanghai, Shanghai Municipality, 200040, China

  • Huashan Hospital Fudan University

    Jingan/Shanghai, 200040, China

  • Huizhou Central People's Hospital-Endocrinology

    Huizhou, Guangdong, 516001, China

  • Jinan Central Hospital

    Ji'nan, Shandong, 250013, China

  • Jinan Central Hospital

    Jin'an, Shandong, 250013, China

  • Jinan Central Hospital

    Jinan, Shandong, 250013, China

  • Shanghai Pudong New Area People's Hospital-Endocrinology

    Shanghai, Shanghai Municipality, 201200, China

  • Suzhou Municipal Hospital-Endocrinology

    Suzhou, Jiangsu, 215002, China

  • The Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212001, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, 221002, China

  • The First Affiliated Hospital of Henan University of Science and Technology-Endocrinology

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Henan university of Science

    Luoyang, Henan, 471003, China

  • The First Affiliated Hospital of Soochow University-Endocrinology

    Suzhou, Jiangsu, 215006, China

  • The First Bethune hospital of Jilin University-Endocrinology

    Changchun, Jilin, 130061, China

  • The First People's Hospital of Changde City-Endocrinology

    Changde, Hunan, 415003, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, 213003, China

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, 213004, China

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011, China

  • The Second Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450003, China

  • The Second Affiliated Hospital of Zhengzhou University-Endocrinology

    Zhengzhou, Henan, 450003, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

  • The Second Hospital of Hebei Medical University-Endocrinology

    Shijiazhuang, Hebei, 050000, China

  • The Second Hospital of Tianjin Medical University

    Tianjin, Tianjin Municipality, 300211, China

  • The first hospital of Jilin University

    Changchun, Jilin, 130021, China

  • Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine

    Shanghai, Shanghai Municipality, 200336, China

  • Tongren Hospital Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200336, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.